Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS)

NCT04789070 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT04789070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04789070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
December 31, 2027
Enrollment
140 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

inclusion body myositis